SUMMARY Shunt thrombosis remains a major cause of morbidity and mortality, especially during the initial palliation for single-ventricle physiology. The authors present evidence that the P2Y 12 inhibitor cangrelor may fill a therapeutic void in thromboprophylaxis. They base this theory on results showing that platelets from neonatal patients with cyanotic congenital heart disease have a robust response to adenosine diphosphate and are amenable to P2Y 12 inhibition with cangrelor. Unique to this study was their ability to establish drug efficacy in an avatar mouse model that permits the in vivo evaluation of human platelet-mediated thrombus formation illustrating that this P2Y 12 (1, 2) . In the latter case, infants (aged <6 months) constitute the major proportion (approximately 70%) of patients seen in tertiary care centers with ATEs (3). In particular, those with single-ventricle physiology who require placement of a systemic-to-pulmonary artery shunt (e.g., modified Blalock-Taussig or central shunts) are at greatest risk, especially in the early post-operative period (3) (4) (5) . Consequently, this scenario has resulted in suboptimal post-operative outcomes as exemplified in a retrospective review of 2,058 neonates who underwent palliation with a systemic-to-pulmonary artery shunt at multiple centers; discharge mortality and complication rates were around an aggregate of 6.7% and 12.3%, respectively (6) . Early institution of aspirin, an irreversible inhibitor of platelet cyclooxygenase, is believed to be beneficial in reducing the risk of shunt occlusion and death (7, 8) , but controversy remains regarding its overall effectiveness. In fact, it has been reported that aspirin alone may not be sufficient to fully inhibit platelet function in the immediate post-operative period (9). Thus, an urgent need remains for additional pharmacological protection to provide adequate thromboprophylaxis for these critically ill patients.
Clopidogrel (a thienopyridine derivative) is an antiplatelet agent that targets the adenosine diphosphate (ADP) receptor P2Y 12 and is known to reduce the risk of ischemia and thrombosis in adult patients during and after percutaneous coronary intervention (PCI) (10, 11) . It does so by impairing P2Y 12 potentiation of platelet-dense granule secretion in response to strong agonists, stabilization of platelet aggregates by contributing to the activation of aIIbb3, and inhibition of the antiplatelet effects of prostacyclin (12) . Despite its proven clinical efficacy in adults with cardiovascular disease, clopidogrel has several major drawbacks that would limit its use in the immediate post-operative period for neonatal cardiac patients.
These drawbacks include the requirement for oral administration that may result in erratic absorption (particularly in bypass cases), delay in the onset of action due to the need for conversion of the pro-drug to an active metabolite, and irreversible inhibition of the P2Y 12 receptor that would necessitate platelet transfusion(s) if bleeding occurred (13) . Interestingly, a previous clinical trial evaluating clopidogrel therapy in infants with cyanotic CHD who underwent palliation with a systemic-to-pulmonary artery shunt failed to show any benefit in reducing the rate of death or shunt-related morbidity in drug-treated patients (14) . This outcome was somewhat surprising as the supraphysiologic shear rates (in excess of 15,000 s À1 ) and shearing forces predicted to occur in artificial conduits connecting the systemic circulation to the pulmonary artery would favor P2Y 12 -mediated platelet activation and aggregation (15) . However, potential shortcomings of this trial were the low 
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A U G U S T 2 0 1 7 : 4 6 5 -7 6 dosage of drug administered and the concomitant use of aspirin in the majority of patients, making it difficult to ascertain the contribution of the P2Y 12 -signaling pathway in supporting platelet aggregation and thrombus formation in these young patients (16) .
Cangrelor, an adenosine triphosphate analogue, is a P2Y 12 receptor antagonist given intravenously with properties more suitable for short-term use; these properties include a rapid, direct, predictable, and reversible inhibition of platelet function (17, 18) . In particular, cangrelor given as a 30-mg/kg bolus followed by a 4-mg/kg/min infusion for 60 min to In the majority of cases, 3.8% trisodium citrate served as an anticoagulant. For microfluidic studies, The ability of ADP and cangrelor to promote or inhibit aggregation of human platelets, respectively, was assessed by using a Lumi-Aggregometer (model 540 VS, Chrono-Log Corp., Havertown, Pennsylvania).
A parallel-plate flow chamber was used to assess human platelet accumulation on surface-immobilized plasma VWF (22, 23) , whereas microfluidic devices were used to evaluate the thrombus growth on a patterned collagen surface (24) .
RESULTS
PATIENT POPULATION. Eighty-eight pediatric patients with CHD, consisting of 3 distinct populations ( 2B and 2C) . To determine whether the P2Y 12 -signaling pathway is robust in platelets from neonatal patients with CHD, we next evaluated the ability of ADP to enable platelets translocating on surface-immobilized VWF, in response to forces generated by flowing blood, to activate and firmly adhere to the substrate by engaging the integrin aIIbb3 (25) . GPIba-VWF interactions are transient in nature due to the rapid kinetic properties of the bond formed between this receptor-ligand pair necessitating integrinmediated firm adhesion for thrombus growth (26) .
Results indicate that this signaling axis is intact as infusion of buffer containing ADP stabilized spheres denote the following: black are residues with buried side chains, green have partially buried side chains, red have exposed side chains on the front and upper surfaces, and gold have exposed side chains on the lower and back surfaces. Circled in blue is residue 1326, which plays a key role in permitting interactions with the GPIba on human and mouse platelets (29) . Accumulation of platelets on (B) surface-immobilized human plasma VWF or (C) murine plasma VWF HA1 is shown. Citrated whole blood from neonatal patients or healthy adults was perfused over the reactive substrate for 3 min (wall shear rate of 1,600 s À1 ) before assessing the number of interacting platelets. (D) Percentage of translocating platelets that became firmly adherent in response to infusion of buffer containing adenosine diphosphate (20 mM). The human GPIba function blocking monoclonal antibody (mAb) 6D1 (10 mg/ml) or the aIIbb3 inhibitor abciximab (10 mg/ml) was added to blood 10 min before use. See Using the identical assay system, we compared the (14) . Clopidogrel, in combination with aspirin therapy, remains a cornerstone in the management of acute coronary syndromes and in patients undergoing An arterial thrombus is composed of distinct regions based on the primary mechanism of platelet activation (28) . Thrombin is believed to drive platelet activation in the early phase of thrombus formation, resulting in a tightly packed core region (dark area) that limits its diffusion to the surface Clearly, these issues underscore the need for antiplatelet agents such as cangrelor that possess pharmacological properties well suited for critically ill neonates with CHD who require thromboprophylaxis.
STUDY LIMITATIONS.
A clinical trial will ultimately be required to determine the PK and PD properties of cangrelor, as well as to assess its safety and efficacy in preventing shunt thrombosis in the immediate postoperative period.
CONCLUSIONS
Platelets isolated from neonatal patients with CHD at the time of surgical repair/palliation have a robust response to ADP and are as amenable to P2Y 12 inhibition with cangrelor as their adult counterparts.
Moreover, our findings seem to be independent of age and type of cardiac lesion. Unique to this study was our ability to establish the in vivo efficacy of cangrelor by using an avatar mouse model that permits real-time evaluation of human platelet interactions with the injured vessel wall, yielding a biological response consistent with P2Y 12 inhibition: disruption of thrombus shell formation. We also illustrated the value of a microfluidic device that can serve as a PD biomarker, requiring significantly less blood to assess changes in platelet reactivity than LTA. This multi-analytic approach will be used in the upcoming clinical trial at our institution that will assess the PK and PD properties of cangrelor in neonatal patients with CHD requiring palliation with a systemicto-pulmonary artery shunt (NCT02765633). Cangrelor for Prevention of Shunt Thrombosis
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